Sign Out
Pregnancy: The use of LEUKERAN should be avoided whenever possible during pregnancy, particularly during the first trimester. In any individual case, the potential hazard to the foetus must be balanced against the expected benefit to the mother.
As with all cytotoxic therapy chemotherapy, adequate contraceptive precautions should be advised when either partner is receiving LEUKERAN.
Lactation: Mothers receiving LEUKERAN should not breastfeed.
Fertility: LEUKERAN may cause suppression of ovarian function and amenorrhoea has been reported following LEUKERAN therapy.
Azoospermia has been observed as a result of therapy with LEUKERAN although it is estimated that a total dose of least 400 mg is necessary. Varying degrees of recovery of spermatogenesis have been reported in patients with lymphoma following treatment with LEUKERAN in total doses of 410 to 2600 mg.
Teratogenicity: As with other cytotoxic agents LEUKERAN is potentially teratogenic.
